pSivida (PSDv) Posts Q3 Loss of 17c/Share

pSivida (NASDAQ: PSDv) reported Q3 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $328 thousand versus the consensus estimate of $600 thousand.

The company announced:

Our licensee Alimera Sciences launched ILUVIEN® in the U.S. for diabetic macular edema (DME) in the quarter. ILUVIEN is now widely available to the estimated 575,000 patients with clinically significant DME in the country. In the U.S. ILLUVIEN is indicated for the treatment of DME in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure.

ILUVIEN was also launched in Portugal in the quarter, making it the third EU market. ILUVIEN has been sold in the U.K. and Germany since 2013. Three more EU countries granted approvals in the quarter, completing the last applications and bringing the number of EU country approvals to 17. ILUVIEN is indicated in the EU for treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. ILUVIEN has been sublicensed in Australia and New Zealand by Alimera.

For earnings history and earnings-related data on pSivida (PSDv) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c